Compare FRMI & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRMI | CMPS |
|---|---|---|
| Founded | 2025 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2025 | 2020 |
| Metric | FRMI | CMPS |
|---|---|---|
| Price | $2.24 | $8.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 16 |
| Target Price | $16.63 | ★ $23.75 |
| AVG Volume (30 Days) | ★ 19.5M | 2.1M |
| Earning Date | 11-12-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $837.34 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.44 | $4.88 |
| 52 Week High | $28.90 | $15.87 |
| Indicator | FRMI | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 29.81 | 28.56 |
| Support Level | N/A | $8.22 |
| Resistance Level | $7.65 | $8.90 |
| Average True Range (ATR) | 0.30 | 0.86 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 4.84 | 20.16 |
Fermi Inc develops next-generation private electric grids that deliver redundant power at gigawatt scale to support next-generation intelligence and AI compute. It combines cutting-edge technology with a deep bench of world-class, multidisciplinary leaders with a combined 25 GW of experience to create one of the world's 17 GW next-gen private grids, helping ensure America's energy and AI dominance. The behind-the-meter Project Matador campus is expected to integrate the nation's combined-cycle natural gas project, one of the clean, new nuclear power complexes in America, utility grid power, solar power, and battery energy storage, to support hyperscale AI and computing.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.